Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation

Cardiovascular Research

Volumn 83, Issue 1, 2009, Pages 155-162

  Ying, Zhekang ^a,c   Giachini, Fernanda R C ^a,b   Tostes, Rita C ^a,b   Webb, Robert Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Contractile function; G proteins; Hypertension; Smooth muscle

Indexed keywords

ACETYLSALICYLIC ACID; CALYCULIN A; FOCAL ADHESION KINASE 2; IBUPROFEN; INDOMETACIN; MYOSIN LIGHT CHAIN PHOSPHATASE; PIROXICAM; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SALICYLATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRESSORECEPTOR; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA, THORACIC; ASPIRIN; BLOOD PRESSURE; BLOOD VESSELS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FOCAL ADHESION KINASE 2; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SALICYLATES; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATION;

EID: 67649369545     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp084     Document Type: Article

References (29)

1. Roberts LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmarcological Basis of Therapeutics. The McGraw-Hill Companies: Columbus, Ohio, USA; 2001. p687-731.
2. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.
3. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
4. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006;24:1457-1469.
5. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-1587.
6. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162:2204-2208.
7. Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005;46:975-983.
8. Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Rodriguez M et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension 2005;46:1060-1068.
9. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358.
10. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929.
11. Hirooka Y, Shimokawa H, Takeshita A. Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect 2004;17:523-527.
12. Ito K, Hirooka Y, Kimura Y, Sagara Y, Sunagawa K. Ovariectomy augments hypertension through rho-kinase activation in the brain stem in female spontaneously hypertensive rats. Hypertension 2006;48:651-657.
13. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K et al. Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 2006;20:169-171.
14. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.
15. Wang Z, Brecher P. Salicylate inhibits phosphorylation of the nonreceptor tyrosine kinases, proline-rich tyrosine kinase 2 and c-Src. Hypertension 2001;37:148-153.
16. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000;12:123-133.
17. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP et al. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci USA 2003;100:10740- 10745.
18. Rocic P, Griffin TM, McRae CN, Lucchesi PA. Altered PYK2 phosphorylation by ANG II in hypertensive vascular smooth muscle. Am J Physiol Heart Circ Physiol 2002;282:H457-H465.
19. Rocic P, Lucchesi PA. Down-regulation by antisense oligonucleotides establishes a role for the proline-rich tyrosine kinase PYK2 in angiotensin II-induced signaling in vascular smooth muscle. J Biol Chem 2001;276:21902-21906.
20. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol 2004;287:H1495-H1500.
21. da Silva AA, Kuo JJ, Tallam LS, Hall JE. Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension 2004;43:383-387.
22. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
23. McEvoy GK. AHFS Drug Information. Bethesda: American Society of Health-System Pharmacist; 2007.
24. Welch WJ, Patel K, Modlinger P, Mendonca M, Kawada N, Dennehy K et al. Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension. Am J Physiol Heart Circ Physiol 2007;293:H2644-H2649.
25. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006;20:2009-2016.
26. Seok YM, Baek I, Kim YH, Jeong YS, Lee IJ, Shin DH et al. Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J Pharmacol Exp Ther 2008;326:991-998.
27. Adegunloye BJ, Su X, Camper EV, Moreland RS. Sensitivity of rabbit aorta and mesenteric artery to norepinephrine: role of tyrosine kinases. Eur J Pharmacol 2003;476:201-209.
28. Fang LH, Kwon SC, Zhang YH, Ahn HY. Tyrosine kinase participates in vasoconstriction through a Ca(2+)- and myosin light chain phosphorylation- independent pathway. FEBS Lett 2002;512:282-286.
29. Matsui A, Okigaki M, Katsume A, Urao N, Yamada H, Matsubara H. Calcium-dependent tyrosine kinase PYK2 plays crucial role in angiotensin II-but not norepinephrine-mediated activation of Rac/superoxide pathway that differentially regulates blood pressure and vasoconstriction unmasked by analysis of PYK2-knock-out mice. Circulation 2008;118:S.316.